A Novel Controlled PTEN-Knockout Mouse Model for Prostate Cancer Study

被引:7
|
作者
Liu, Sen [1 ]
Zhang, Bing [1 ,2 ]
Rowan, Brian G. [1 ]
Jazwinski, S. Michal [3 ,4 ]
Abdel-Mageed, Asim B. [5 ]
Steele, Chad [6 ]
Wang, Alun R. [7 ]
Sartor, Oliver [5 ,8 ]
Niu, Tianhua [9 ]
Zhang, Qiuyang [1 ,4 ,8 ]
机构
[1] Tulane Univ, Sch Med, Dept Struct & Cellular Biol, 1430 Tulane Ave, New Orleans, LA 70112 USA
[2] ShenZhen LuoHu Peoples Hosp, Med Lab, Shenzhen, Peoples R China
[3] Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA
[4] Tulane Univ, Sch Med, Tulane Ctr Aging, 1430 Tulane Ave, New Orleans, LA 70112 USA
[5] Tulane Univ, Sch Med, Dept Urol, New Orleans, LA 70112 USA
[6] Tulane Univ, Sch Med, Dept Microbiol & Immunol, New Orleans, LA 70112 USA
[7] Tulane Univ, Sch Med, Dept Pathol & Lab Med, 1430 Tulane Ave, New Orleans, LA 70112 USA
[8] Tulane Univ, Sch Med, Tulane Canc Ctr, 1430 Tulane Ave, New Orleans, LA 70112 USA
[9] Tulane Univ, Sch Med, Dept Biochem & Mol Biol, 1430 Tulane Ave, New Orleans, LA 70112 USA
基金
美国国家卫生研究院;
关键词
cre-expressing adenovirus; age; prostate cancer; Pten; mouse models; TUMOR-SUPPRESSOR GENE; TRANSGENIC MOUSE; CRE RECOMBINASE; MICE; INACTIVATION; PTEN/MMAC1; EXPRESSION; DELETION; PATHWAY; LEADS;
D O I
10.3389/fmolb.2021.696537
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Prostate cancer (PCa) is associated with advanced age, but how age contributes to prostate carcinogenesis remains unknown. The prostate-specific Pten conditional knockout mouse model closely imitates human PCa initiation and progression. To better understand how age impacts PCa in an experimental model, we have generated a spatially and temporally controlled Pten-null PCa murine model at different ages (aged vs. non-aged) of adult mice. Here, we present a protocol to inject the Cre-expressing adenovirus with luciferin tag, intraductally, into the prostate anterior lobes of Pten-floxed mice; Pten-loss will be triggered post-Cre expression at different ages. In vivo imaging of luciferin signal following viral infection confirmed successful delivery of the virus and Cre activity. Immunohistochemical staining confirmed prostate epithelial-specific expression of Cre recombinase and the loss of Pten and activation of P-Akt, P-S6, and P-4E-BP1. The Cre-expression, Pten ablation, and activated PI3K/AKT/mTOR pathways were limited to the prostate epithelium. All mice developed prostatic epithelial hyperplasia within 4 weeks after Pten ablation and prostatic intraepithelial neoplasia (PIN) within 8 weeks post-Pten ablation. Some PINs had progressed to invasive adenocarcinoma at 8-16 weeks post-Pten ablation. Aged mice exhibited significantly accelerated PI3K/AKT/mTOR signaling and increased PCa onset and progression compared to young mice. The viral infection success rate is similar to 80%. This model will be beneficial for investigations of cancer-related to aging.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] A novel human cancer culture model for the study of prostate cancer
    Yutaka Yasunaga
    Keiichiro Nakamura
    Daejin Ko
    Shiv Srivastava
    Judd W Moul
    Isabell A Sesterhenn
    David G McLeod
    Johng S Rhim
    Oncogene, 2001, 20 : 8036 - 8041
  • [32] A novel human cancer culture model for the study of prostate cancer
    Yasunaga, Y
    Nakamura, K
    Ko, DJ
    Srivstava, S
    Moul, JW
    Sesterhenn, IA
    McLeod, DG
    Rhim, JS
    ONCOGENE, 2001, 20 (55) : 8036 - 8041
  • [33] Histopathological characteristics of a novel knock-in mouse prostate cancer model
    Wu, G.
    Wang, D.
    Wang, H.
    Yuan, J.
    Xuan, J. W.
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2006, 39 (06) : 759 - 765
  • [34] Hormone refractory prostate cancer: Lessons learned from the PTEN prostate cancer model
    Mulholland, David J.
    Jiao, Jing
    Wu, Hong
    HORMONAL CARCINOGENESIS V, 2008, 617 : 87 - 95
  • [35] Withaferin A Inhibits Prostate Carcinogenesis in a PTEN-deficient Mouse Model of Prostate Cancerle
    Moselhy, Jim
    Suman, Suman
    Alghamdi, Mohammed
    Chandarasekharan, Balaji
    Das, Trinath P.
    Houda, Alatassi
    Ankem, Murali
    Damodaran, Chendil
    NEOPLASIA, 2017, 19 (06): : 451 - 459
  • [36] Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer
    Yamamoto, Yutaka
    De Velasco, Marco A.
    Kura, Yurie
    Nozawa, Masahiro
    Hatanaka, Yuji
    Oki, Takashi
    Ozeki, Takayuki
    Shimizu, Nobutaka
    Minami, Takafumi
    Yoshimura, Kazuhiro
    Yoshikawa, Kazuhiro
    Nishio, Kazuto
    Uemura, Hirotsugu
    JOURNAL OF TRANSLATIONAL MEDICINE, 2015, 13
  • [37] Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer
    Emma H. Allott
    Elizabeth M. Masko
    Alexis R. Freedland
    Everardo Macias
    Kristine Pelton
    Keith R. Solomon
    Elahe A. Mostaghel
    George V. Thomas
    Salvatore V. Pizzo
    Michael R. Freeman
    Stephen J. Freedland
    Prostate Cancer and Prostatic Diseases, 2018, 21 : 196 - 203
  • [38] Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer
    Allott, Emma H.
    Masko, Elizabeth M.
    Freedland, Alexis R.
    Macias, Everardo
    Pelton, Kristine
    Solomon, Keith R.
    Mostaghel, Elahe A.
    Thomas, George, V
    Pizzo, Salvatore, V
    Freeman, Michael R.
    Freedland, Stephen J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2018, 21 (02) : 196 - 203
  • [39] Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer
    Yutaka Yamamoto
    Marco A De Velasco
    Yurie Kura
    Masahiro Nozawa
    Yuji Hatanaka
    Takashi Oki
    Takayuki Ozeki
    Nobutaka Shimizu
    Takafumi Minami
    Kazuhiro Yoshimura
    Kazuhiro Yoshikawa
    Kazuto Nishio
    Hirotsugu Uemura
    Journal of Translational Medicine, 13
  • [40] A Nod Scid mouse model to study human prostate cancer
    C Bastide
    C Bagnis
    P Mannoni
    J Hassoun
    F Bladou
    Prostate Cancer and Prostatic Diseases, 2002, 5 : 311 - 315